Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectus BiosystemsASX:VBS +9.38%15 Beneish M-Score is 0.00 as of Jul. 13, 2026. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 825 Biotechnology companies, Vectus Biosystems ranks worse than 121212% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
The historical rank and industry rank for Vectus Biosystems's Beneish M-Score or its related term are showing as below:
During the past 10 years, the highest Beneish M-Score of Vectus Biosystems was 0.00. The lowest was 0.00. And the median was 0.00.
Vectus Biosystems Beneish M-Score Related Terms
Vectus Biosystems Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Vectus Biosystems's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VBS vs VRTX, REGN, ALNY: Beneish M-Score Comparison
For the Biotechnology subindustry, Vectus Biosystems's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectus Biosystems Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Vectus Biosystems's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Vectus Biosystems for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 *
+
0.528 *
+
0.404 *
+
0.892 *
+
0.115 *
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 *
+
4.679 *
-
0.327 *
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0.059 / (0.059 + 0.182))
/
(0.014 / (0.014 + 0.004))
=
0.244813
/
0.777778
=
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-1.777 - 0.387
-
-0.83)
/
0.783
=
-1.703704
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Vectus Biosystems (ASX:VBS) has a Beneish M-Score of 0.00 as of Jul. 13, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vectus Biosystems and its competitors. According to the industry distribution chart, Vectus Biosystems ranks #999999 out of 825 companies in the Biotechnology industry.
Is Vectus Biosystems' Beneish M-Score too high?
Vectus Biosystems' current Beneish M-Score is 0.00. Based on the distribution chart, Vectus Biosystems ranks #999999 out of 825 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #999999 out of 825 companies for Beneish M-Score. This places Vectus Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vectus Biosystems and its competitors. Vectus Biosystems's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Beneish M-Score is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score
Get the complete analysis for ASX:VBS
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VBS has been successfully added to your 
